Evidence map›Paper›PMID 28480334›Full record

ArticlePapillomavirus research (Amsterdam, Netherlands)2017

HPV SEROSTATUS PRE- AND POST-VACCINATION IN A RANDOMIZED PHASE II PREPAREDNESS TRIAL AMONG YOUNG WESTERN CAPE, SOUTH AFRICAN WOMEN: THE EVRI TRIAL.

Staci L Sudenga, B Nelson Torres, Matthys H Botha, Michele Zeier, Martha E Abrahamsen, Richard H Glashoff, Susan Engelbrecht, Maarten F Schim Van der Loeff, Louvina E Van der Laan, Siegfried Kipping and 2 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Papillomavirus research (Amsterdam, Netherlands), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01489527 (Preparedness Study), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01489527 nacompletednot on this map

Preparedness Study: Efficacy of HPV Vaccine to Reduce HIV Infection

TypeinterventionalSponsorH. Lee Moffitt Cancer Center and Research InstituteRan2012 to 2014Enrolled406ConditionsSexual Transmission of InfectionArmsGardasil Vaccine, Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Staci L SudengaCenter for Infection Research in Cancer, Moffitt Cancer Center, Tampa, FL, USA.
B Nelson TorresCenter for Infection Research in Cancer, Moffitt Cancer Center, Tampa, FL, USA.
Matthys H BothaDepartment of Obstetrics and Gynaecology and Unit for Gynaecological Oncology, Tygerberg Hospital, Stellenbosch University, Cape Town, South Africa.
Michele ZeierDepartment of Medicine and Centre for Infectious Diseases, Stellenbosch University, Cape Town, South Africa.
Martha E AbrahamsenCenter for Infection Research in Cancer, Moffitt Cancer Center, Tampa, FL, USA.
Richard H GlashoffDivision of Medical Virology, Stellenbosch University and NHLS Tygerberg, Cape Town, South Africa.
Susan EngelbrechtDivision of Medical Virology, Stellenbosch University and NHLS Tygerberg, Cape Town, South Africa.
Maarten F Schim Van der LoeffDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
Louvina E Van der LaanDepartment of Obstetrics and Gynaecology and Unit for Gynaecological Oncology, Tygerberg Hospital, Stellenbosch University, Cape Town, South Africa.
Siegfried KippingDepartment of Obstetrics and Gynaecology and Unit for Gynaecological Oncology, Tygerberg Hospital, Stellenbosch University, Cape Town, South Africa.
Douglas TaylorFHI 360, Durham, NC, USA.
Anna R GiulianoCenter for Infection Research in Cancer, Moffitt Cancer Center, Tampa, FL, USA.

Funding

Moffitt Postdoctoral Training Program in Molecular & Genetic EpidemiologyR25CA147832 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI EGAN, KATHLEEN M. · 2010 to 2014
$2.0M
NCI NIH HHS R25 CA147832
6 · The paper itself

Abstract

backgroundHPV antibodies are a marker of past exposure to the virus. Our objective was to assess HPV serostatus pre- and post-vaccination among HIV-negative women.

methodsWomen aged 16-24 years old were randomized in a placebo controlled trial utilizing the 4-valent HPV (4vHPV) vaccine (NCT01489527, clinicaltrials.gov). Participants (n=389) received the 4vHPV vaccine or placebo following a three dose schedule. Sera were collected at Day 1 and Month 7 for assessment of HPV 6, 11, 16, and 18 neutralizing antibody levels using a multiplex competitive Luminex immunoassay (Merck) based on detecting the L1 capsid antigen for each HPV type.

resultsSeroprevalence was 73% for HPV6, 47% for HPV11, 33% for HPV16, and 44% for HPV18. Seroprevalence for any HPV type did not significantly differ by age or lifetime number of partners. The majority of participants (64%) had two or more 4vHPV antibodies present at enrollment and 12% had antibodies to all four. Among women in the vaccine arm, those that were seropositive for HPV16 at enrollment had higher titers at month 7 compared to women that were seronegative for HPV16 at enrollment; this trend holds for the other HPV types as well. Seroconversion among baseline seronegative participants in the placebo group ranged from 5% for HPV16 to 23% for HPV6.

conclusionHPV seroprevalence was high in this population, emphasizing the need to vaccinate prior to sexual debut.

Indexed as

cLIAEVRIHPV vaccineseroprevalence

Identifiers

PMID28480334
PMCPMC5417542

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.